Nurullah İlhan,MD· @drnurullahilhan · X·· 19 小时前评分70
正文 · 原文
FOURLIGHT-1: HR+/HER2− breast cancer after CDK4/6i.
Atirmociclib + fulvestrant met the phase II PFS endpoint:
9.4 vs 6.6 months; HR 0.60.
Control: fulvestrant OR everolimus/exemestane.
Separate superiority over the latter was not shown.
#FOURLIGHT1 #ESMO2026 #BCSM
8 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Nurullah İlhan,MD · x.com